Rafael Fridman

Rafael Fridman



Rafael Fridman

Office Address

Department of Pathology
540 E. Canfield Ave, Room 8200
Detroit, MI 48201

Administrative Contact

Brenda Batts

Position Title

Leader of Proteases and Cancer Program of the Barbara Ann Karmanos Cancer Institute

Education Training

Ph.D. (1986): Hebrew University, Jerusalem, Israel

Postdoctoral Fellowship
1987-1990: National Institutes of Health, Bethesda, MD, USA, in the field of Tumor Biology

Areas of Interest

Matrix metalloproteinases, proteases, protease inhibitors, prostate cancer, and bone metastasis

Research Interests


1. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y, Meroueh O, Kotra LP, Galvez BG, Arroyo AG, Mobashery S, and Fridman R, 2002, Complex pattern of membrane type 1-matrix metalloproteinase shedding regulation by autocatalytic cell surface inactivation of active enzyme, J Biol Chem, 277: 26340-50.
2. Kruger A, Arlt M, Gerg M, Bernardo MM, Kopitz C, Chang M, Mobashery S and Fridman R, 2005, Antimetastatic activity of a novel mechanism-based gelatinase inhibitor,  Cancer Res, 65: 3523-6.
3. Sun Q, Weber CR, Sohail A, Bernardo MM, Toth M, Zhao H, Turner JR, and Fridman R, 2007, MT6-MMP is highly expressed in human colon cancer, promotes tumor growth and exhibits unique biochemical properties, J Biol Chem, 282: 21998-2010.
4. Cho J-A, Osenkowski P, Zhao H, Kim S, Toth M, Cole K, Aboukameel A,  Saliganan A, Schuger L, Bonfil  RD,  and Fridman R, 2008, The inactive 44-kDa processed form of MT1-MMP enhances proteolytic activity via regulation of endocytosis of active MT1-MMP,  J Biol Chem, 283: 17391-405.
5. Sohail A, Sun Q, Zhao H, Bernardo MM, Cho J-A and Fridman R, 2008, MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer,  Cancer Met Rev, 27: 289-302.

← Return to listing